FDA Adds Fasenra Indication for Severe Asthma in Children
By Lori Solomon HealthDay Reporter
TUESDAY, April 16, 2024 -- The U.S. Food and Drug Administration has approved an additional indication for Fasenra (benralizumab) as an add-on maintenance treatment for patients aged 6 to 11 years with severe asthma and an eosinophilic phenotype.
This indication was supported by evidence from the phase 3 TATE trial, as well as data from additional well-controlled trials in adult and adolescent populations. Results among children aged 6 to 11 years old show that Fasenra met the primary end points, demonstrating pharmacokinetics and pharmacodynamics with severe eosinophilic asthma. The safety and tolerability results were also consistent with the known profile.
The recommended dose for Fasenra is 30 mg for patients ages 6 years and older who weigh ≥35 kg, while a new 10-mg dose will be available for patients aged 6 to 11 years who weigh <35 kg. Fasenra is administered by subcutaneous injection every four weeks for the first three doses and then every eight weeks.
"We welcome additional treatment options for children living with severe asthma, a condition that remains complicated to manage, further helping to address the unmet need in this patient population and reducing the burden of disease for the broader asthma community," Lynda Mitchell, of the Allergy & Asthma Network, said in a statement.
Approval of this indication for Fasenra was granted to AstraZeneca.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Few Adults With Moderate, Severe Asthma Receive Recommended Inhaler Regimen
THURSDAY, May 23, 2024 -- Only 14.5 percent of adult patients with moderate or severe asthma are prescribed the recommended Single Maintenance and Reliever Therapy (SMART) inhaler...
Researchers Compare Race-Based, Race-Neutral Lung Function Equations
TUESDAY, May 21, 2024 -- The use of race-based and race-neutral equations for lung-function testing generate similarly accurate predictions of respiratory outcomes, but differ in...
Pulmonologist Intervention Beneficial for Undiagnosed Asthma, COPD
TUESDAY, May 21, 2024 -- For adults with undiagnosed asthma and chronic obstructive pulmonary disease (COPD), receipt of pulmonologist-directed treatment is associated with less...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.